A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity

Journal of Pharmaceutical Sciences

Volumn 102, Issue 5, 2013, Pages 1626-1635

  Yuan, Ahu ^a   Wu, Jinhui ^a,c   Song, Chenchen ^a   Tang, Xiaolei ^a   Qiao, Qian ^a   Zhao, Lili ^a   Gong, Guangming ^b   Hu, Yiqiao ^a  

^a NANJING UNIVERSITY   (China)

^b NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

^c Center for Novel Drug Development of Taizhou   (China)

Author keywords

Albumin; Cancer; Cardiotoxicity; Doxorubicin; Drug delivery; Nanoparticles; Protein binding

Indexed keywords

CREATINE KINASE MB; DOXORUBICIN; HUMAN SERUM ALBUMIN; LACTATE DEHYDROGENASE; MALONALDEHYDE; NANOCARRIER; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARDIOTOXICITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG ACCUMULATION; HEART LEFT VENTRICLE EJECTION FRACTION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER CELL CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PARTICLE SIZE;

EID: 84876337793     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23455     Document Type: Article

References (41)

1. Xiao K, Luo J, Li Y, Lee JS, Fung G, Lam KS. 2011. PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. J Control Release 155(2):272-281.
2. Box VG. 2007. The intercalation of DNA double helices with doxorubicin and nogalamycin. J Mol Graph Model 26(1):14-19.
3. Bridewell DJ, Finlay GJ, Baguley BC. 1997. Differential actions of aclarubicin and doxorubicin: The role of topoisomerase I. Oncol Res 9(10):535-542.
4. Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM. 2006. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 66(9):4863-4871.
5. Fu Z, Guo J, Jing L, Li R, Zhang T, Peng S. 2010. Enhanced toxicity and ROS generation by doxorubicin in primary cultures of cardiomyocytes from neonatal metallothionein-I/II null mice. Toxicol In Vitro 24(6):1584-1591.
6. Fazio S, Palmieri EA, Ferravante B, Bone F, Biondi B, Sacca L. 1998. Doxorubicin-induced cardiomyopathy treated with carvedilol. Clin Cardiol 21(10):777-779.
7. Rahman AM, Yusuf SW, Ewer MS. 2007. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomed 2(4):567-583.
8. 2. Ann Oncol 11(8):1029-1033.
9. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C. 2004. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15(3):440-449.
10. Lukyanov AN, Torchilin VP. 2004. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev 56(9):1273-1289.
11. Kaminskas LM, McLeod VM, Kelly BD, Cullinane C, Sberna G, Williamson M, Boyd BJ, Owen DJ, Porter CJ. 2012. Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models. Mol Pharm 9(3):422-432.
12. Ren D, Kratz F, Wang SW. 2011. Protein nanocapsules containing doxorubicin as a pH-responsive delivery system. Small 7(8):1051-1060.
13. Barenholz Y. 2012. Doxil(R)-The first FDA-approved nano-drug: Lessons learned. J Control Release 160(2):117-134.
14. Immordino ML, Dosio F, Cattel L. 2006. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 1(3):297-315.
15. Mozafari MR. 2005. Liposomes: An overview of manufacturing techniques. Cell Mol Biol Lett 10(4):711-719.
16. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J. 1995. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75(8):2169-2173.
17. Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. 2007. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ("hand-foot" syndrome). Ann Oncol 18(7):1159-1164.
18. Kaminskas LM, McLeod VM, Kelly BD, Cullinane C, Sberna G, Williamson M, Boyd BJ, Owen DJ, Porter CJ. 2012. Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models. Mol Pharm 9(3):422-432.
19. Elsadek B, Kratz F. 2012. Impact of albumin on drug delivery-New applications on the horizon. J Control Release 157(1):4-28.
20. Kratz F, Elsadek B. 2011. Clinical impact of serum proteins on drug delivery. J Control Release 161(2):429-445.
21. Kratz F. 2008. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Control Release 132(3):171-183.
22. Kratz F, Beyer U. 1998. Serum proteins as drug carriers of anticancer agents: A review. Drug Deliv 5(4):281-299.
23. Wilson B, Ambika TV, Patel RD, Jenita JL, Priyadarshini SR. 2012. Nanoparticles based on albumin: Preparation, characterization and the use for 5-flurouracil delivery. Int J Biol Macromol 51(5):874-888.
24. Wagner S, Rothweiler F, Anhorn MG, Sauer D, Riemann I, Weiss EC, Katsen-Globa A, Michaelis M, Cinatl J, Jr., Schwartz D, Kreuter J, von Briesen H, Langer K. 2010. Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 31(8):2388-2398.
25. Bae S, Ma K, Kim TH, Lee ES, Oh KT, Park ES, Lee KC, Youn YS. 2012. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials 33(5):1536-1546.
26. Hawkins MJ, Soon-Shiong P, Desai N. 2008. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60(8):876-885.
27. Rideout K, Teschke K, Dimich-Ward H, Kennedy SM. 2005. Considering risks to healthcare workers from glutaraldehyde alternatives in high-level disinfection. J Hosp Infect 59(1):4-11.
28. Furst W, Banerjee A. 2005. Release of glutaraldehyde from an albumin-glutaraldehyde tissue adhesive causes significant in vitro and in vivo toxicity. Ann Thorac Surg 79(5):1522-1528; discussion 1529.
29. Gong G, Zhi F, Wang K, Tang X, Yuan A, Zhao L, Ding D, Hu Y. 2011. Fabrication of a nanocarrier system through self-assembly of plasma protein and its tumor targeting. Nanotechnology 22(29):295603.
30. Gong G, Xu Y, Zhou Y, Meng Z, Ren G, Zhao Y, Zhang X, Wu J, Hu Y. 2012. Molecular switch for the assembly of lipophilic drug incorporated plasma protein nanoparticles and in vivo image. Biomacromolecules 13(1):23-28.
31. Wu J, Wu L, Xu X, Yin X, Chen Y, Hu Y. 2009. Microspheres made by w/o/o emulsion method with reduced initial burst for long-term delivery of endostar, a novel recombinant human endostatin. J Pharm Sci 98(6):2051-2058.
32. Hwang JY, Park J, Kang BJ, Lubow DJ, Chu D, Farkas DL, Shung KK, Medina-Kauwe LK. 2012. Multimodality imaging in vivo for preclinical assessment of tumor-targeted doxorubicin nanoparticles. PLoS One 7(4):e34463.
33. Jiang J, Yang SJ, Wang JC, Yang LJ, Xu ZZ, Yang T, Liu XY, Zhang Q. 2010. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. Eur J Pharm Biopharm 76(2):170-178.
34. Almeida JP, Chen AL, Foster A, Drezek R. 2011. In vivo biodistribution of nanoparticles. Nanomedicine (Lond) 6(5):815-835.
35. Bernard Y, Ribeiro N, Thuaud F, Turkeri G, Dirr R, Boulberdaa M, Nebigil CG, Desaubry L. 2011. Flavaglines alleviate doxorubicin cardiotoxicity: Implication of Hsp27. PLoS One 6(10):e25302.
36. Bae Y, Nishiyama N, Fukushima S, Koyama H, Yasuhiro M, Kataoka K. 2005. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: Tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug Chem 16(1):122-130.
37. Barraud L, Merle P, Soma E, Lefrancois L, Guerret S, Chevallier M, Dubernet C, Couvreur P, Trepo C, Vitvitski L. 2005. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol 42(5):736-743.
38. Zarghami N, Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Sismondi P, Diamandis EP. 1996. Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients. Br J Cancer 73(3):386-390.
39. Afanas'ev I. 2011. ROS and RNS signaling in heart disorders: Could antioxidant treatment be successful? Oxidative Med Cell Longevity 293769:1-13.
40. Belch JJ, Bridges AB, Scott N, Chopra M. 1991. Oxygen free radicals and congestive heart failure. Br Heart J 65(5):245-248.
41. Zhang C, Wang W, Liu T, Wu Y, Guo H, Wang P, Tian Q, Wang Y, Yuan Z. 2012. Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy. Biomaterials 33(7):2187-2196.